XNAS · ALXO
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
ALX Oncology Holdings Inc. Common Stock

ALX Oncology Holdings Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$2.07
+ Add to watchlist
Card

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is ALXO moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About ALX Oncology Holdings Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Listed since
2020
Employees
43
Country
US

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.07
Last session
Day high
$2.07
Last session
Day low
$2.07
Last session
Previous close
$2.07
52W high
$2.23
-7.17% from high
52W low
$1.38
81% of range
Market cap
$278.5M
EPS
$-1.6500
Shares out
134.6M
VWAP
$2.07
Last session
Price history computed in-house
1W
+3.50%
SMA 50 $1.73 · above
SMA 200 $1.73 · above
52W position 81%
Veridion warehouse edge

Warehouse intelligence for ALXO.

Veridion Score
82
0: 871: 652: 533: 704: 775: Not reported
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

ALXO insider activity

ALX Oncology Holdings Inc. Common Stock

Score
Coverage building
Pressure
Mixed
Filings
0
Buys / sells
0 / 0
Net value
Not disclosed
Insiders
0
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Mixed: Not disclosed across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Coverage building

The current Form 4 feed did not return value-bearing open-market rows for ALXO.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

ALXO contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ALXO in this window.
Lobbying spend

ALXO lobbying filings, year to date.

Registered lobbying filings matched to ALX Oncology Holdings Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ALXO in this window.
Latest news · ALXO
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for ALXO.
Options
Sovereign unlock shows live options positioning for ALXO.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.